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Background: The transcription factor, Sox2, is central to the behaviour of neural stem cells. It is also one of the
key embryonic stem cell factors that, when overexpressed can convert somatic cells into induced pluripotent cells.
Although generally studied as a transcriptional activator, recent evidence suggests that it might also repress gene
expression.
Results: We show that in neural stem cells Sox2 represses as many genes as it activates. We found that Sox2
interacts directly with members of the groucho family of corepressors and that repression of several target genes
required this interaction. Strikingly, where many of the genes activated by Sox2 encode transcriptional regulators,
no such genes were repressed. Finally, we found that a mutant form of Sox2 that was unable to bind groucho
was no longer able to inhibit differentiation of neural stem cells to the same extent as the wild type protein.
Conclusions: These data reveal a major new mechanism of action for this key transcription factor. In the context of
our understanding of endogenous stem cells, this highlights the need to determine how such a central regulator
can distinguish which genes to activate and which to repress.
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Sox2 is a central player in animal development and one
of only a few factors that together can initiate the forma-
tion of pluripotent cells (iPS cells) from somatic cell
populations [1,2]. This reflects its central role as a ‘node’
in the gene regulatory network that controls embryonic
stem cell biology, promoting stem cell self-renewal and
inhibiting differentiation. Sox2 is also one of the first
genes to be active in the neural ectoderm and its expres-
sion is maintained in proliferating neural stem cells
(NSCs) of the CNS throughout development and in the
mature brain [3,4]. The expression of Sox2 in these cells
again seems to be associated with their self-renewal and
inhibition of differentiation [5]. Sox2 is generally regarded
as a transcriptional activator. However, in recent studies
analysing the global response of cells to loss of Sox2 activ-
ity, the expression of many genes was seen to increase* Correspondence: paul.scotting@nottingham.ac.uk
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unless otherwise stated.rapidly when Sox2 function was inhibited [6,7]. ChIP-seq
analysis shows that several of the genes affected in these
studies are directly bound by Sox2, implying that they are
direct targets [8-11]. Given the central role of Sox2 in the
biology of both ES cells and NSCs, the possibility that it
might also possess such a major alternative mechanism of
action is of great interest. We therefore set out to deter-
mine to what extent Sox2 represses genes in NSCs. Using
an expression array approach, we found that Sox2 re-
pressed approximately as many genes as it activated
in NSCs.
We also investigated the mechanism by which Sox2
might achieve transcriptional repression. Tcf and Lef are
closely related to the Sox gene family. These factors can
act as either transcriptional activators or repressors. Like
many other transcriptional repressors, these proteins
achieve this effect by recruiting members of the groucho-
related gene (Grg) family of co-repressors [12]. We con-
sidered this to be a likely route for the repressor activity
of Sox2.
We found that Sox2 can indeed interact with Grg pro-
teins and a mutation disrupting interaction between Sox2This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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repress expression from the GFAP promoter whilst its
ability to activate other promoters remained intact. We
also found that, unlike wild type (WT) Sox2, the mu-
tant version of Sox2 was unable to repress neuronal
differentiation when overexpressed. This suggests a new
model for the mechanisms by which Sox2 regulates
NSC biology.
Results
Elucidating the target genes of Sox2 repression
In order to ascertain the extent to which Sox2 acti-
vates and represses genes in NSCs, we carried out
gene expression microarray analysis. Human NSCs
were transfected with expression constructs encoding
EGFP alone, or together with WT Sox2. After 14 hours in
culture, EGFP-expressing cells were isolated by FACS and
RNA extracted for analysis using Affymetrix Human
Genome U133 Plus 2.0 chips (Figure 1A, see Additional
file 1: Table S1).
RT-qPCR revealed that the level of Sox2 overexpres-
sion was approximately 6 fold greater than endogenous
Sox2 and expression of the endogenous Sox2 gene was
unaffected in transfected cells. (data not shown). Among
the genes that were affected by Sox2 (>1.5 fold change
as compared to cells transfected with EGFP alone), the
number exhibiting repressed probe sets (650, 5% of genes
on the array) was almost the same as the number activated
(652) (Figure 1B, C). These numbers are strikingly similar
to the number of genes whose expression increased (623)
or decreased (648) >1.5 fold when Sox2 expression
was lost (using inducible Sox2-null mice) in ES cells
(Masui et al. [6]).
Comparison of the genes activated by Sox2 to those
repressed revealed a striking difference. According to
their gene ontology (GO) terms (Using the Gorilla tool
[13]) genes that were activated by Sox2 were highly
enriched for those listed under terms related to regu-
lating transcription (see Additional file 2: Table S2 and
Additional file 3: Table S3). Most of these represent tran-
scription factors. Remarkably, the list of genes repressed
by Sox2, included no terms in these same GO term cat-
egories. By contrast, among the genes repressed by
Sox2, there was very strong enrichment for genes asso-
ciated with the cell cycle and mitosis, including spindle
organization and DNA replication and repair. Such a
dramatic difference in the classes of gene activated or
repressed by Sox2 provides additional assurance that
the genes identified are a non-random selection of the
genes on the array.
Previous studies in which Sox2 was knocked down
were carried out in ES cells and so would not be expected
to share much in common with our experiments in NSCs.
However, comparison between these data revealed a smallproportion of the genes identified as repressed by Sox2 in
our study that were also repressed by Sox2 in ES cells.
Some of these genes have also been shown to be bound
by Sox2 by ChIPseq (Masui et al. [6]; Greber et al. [7])
(Figure 1D).Sox2 interacts with Grg proteins
Other HMG domain factors have been shown to interact
with the Grg family of co-repressors [14,15]. Therefore, in
order to determine if this might also be a potential mech-
anism by which Sox2 could act as a transcriptional repres-
sor, we used two assays. First, we determined if Sox2
could alter the subcellular localization of Grg proteins.
There are five Grg genes in vertebrates; Grg1-4 are long
forms and Grg 5 is equivalent to only the N-terminal half
of those long forms. We analysed Grg5 and Grg3 as a rep-
resentative full length Grg protein. When transfected into
COS-7 cells, Grg3 forms nuclear bodies, Grg5 is seen in
both the nucleus and the cytoplasm and Sox2 exhibits
diffuse staining restricted to the nucleus (Figure 2A, see
Additional file 4: Figure S1A). When co-transfected with
Sox2, both Grg3 and Grg5 adopted exclusively diffuse nu-
clear staining matching the distribution of Sox2, suggest-
ing an interaction between Sox2 and Grgs (Figure 2B, C).
In a second assay, co-immunoprecipitation was carried
out using human NSCs, (which are known to express
Sox2) transfected with MYC-tagged Grgs. This showed
that endogenous Sox2 was co-precipitated with the MYC-
tagged Grg3 and Grg5 implying that they exist in a protein
complex (Figure 2D).Grgs affect Sox2 function
To determine if Grgs affect the transcriptional regulation
activity of Sox2, luciferase reporter assays were carried
out using several promoter sequences. Co-transfection
of COS-7 cells with Sox2 resulted in a twofold increase
in luciferase expression from a ‘generic’ Sox promoter
(pTl/3xSX, which has three Sox binding sites upstream
of the luciferase reporter gene) and a 25-fold increase
when the luciferase gene was under the control of the
REX gene proximal promoter element, a known target of
Sox2 [16]. When Grg3 or Grg5 constructs were also
transfected alongside Sox2, these increases in luciferase
activity were almost completely abrogated or severely
reduced (Figure 3A, B). According to Cavellaro et al. [17],
expression of the GFAP gene is directly repressed by Sox2.
Here, we confirmed this in P19 EC cells, in which the
basal level of luciferase activity was significantly repressed
by co-transfected Sox2 (Figure 3C). This repression was
even greater in the presence of co-transfected Grg3 or
Grg5 (Figure 3C), where transfection of the same amount
of Grg3 or Grg5 alone had no significant effect on the
luciferase expression (Figure 3D).
Figure 1 Potential target genes of Sox2-Grg interaction. (A) Scheme of the experiment using microarray analysis to identify genes affected
by Sox2 in human NSCs. (B) The relative percentage of genes affected by Sox2 as compared to control cells transfected by GFP alone (only
differences of above 1.5-fold were included in both comparisons). (C) Graph representing the most activated (bars to right of midline) and
repressed (bars to left of midline) genes. (D) The genes most strongly repressed by Sox2 in our study that were also suggested to be repressed
by Sox2 in mouse ES cells (Masui et al. [6]), or in human ES cells (Greber et al. [7]). Final column indicates the study in which these were also
shown to be direct targets of Sox2.
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We designed six C-terminal deletions of Sox2 (Figure 4A)
and tested their ability to interact with Grgs (all the con-
structs produced Sox2 protein that still located to the
nucleus, see Additional file 4: Figure S1). The subcellulartranslocation assay with Grg5 indicated that the C-ter-
minal amino acids between 203 and 209 were essential for
the interaction (Figure 4A). We therefore set out to gener-
ate a site-directed mutant that no longer bound Grgs, but
would retain transcriptional activator activity.
Figure 2 Sox2 interacts with Grg proteins. (A) subcellular localization of overexpressed MYC-tagged Grg3 or Grg5 in COS-7 cells; immunostaining
with anti-Sox2 or anti-MYC antibody. Nuclei were stained with DAPI. (B) Co-transfection of Sox2 with either Grg3 or Grg5, caused the subcellular
distribution of the Grgs (red) to alter to reflect that of Sox2 (green). (C) Quantification of cytoplasmic Grg5 using Image J software shows effect of Sox2
on Grg5 subcellular distribution was highly significant (p = 0.0023). (D) Immunoprecipitation of overexpressed MYC-tagged Grg3 or Grg5 in human
neural stem cells, after treatment with DPS crosslinker, resulted in co-precipitation of endogenous Sox2. Left hand blot was probed for the Grgs using
anti-MYC, right hand panel probed for Sox2 using annti-Sox2 antibody. WCE - whole cell extract. Size markers in lanes 3 and 9, sizes shown to right of
image. Scale bar in for panel A and B approximately 10 μm.
Liu et al. BMC Neuroscience 2014, 15:95 Page 4 of 10
http://www.biomedcentral.com/1471-2202/15/95Loss of Grg interaction in a 203–209 mutant
Comparison between Sox2 and the other SoxB1 members
and between Sox2 orthologues from different species
revealed that only four amino acids were conserved
in the region from position 203–209. We therefore
made a mutant, referred to as Sox2M203–209, in which
these four amino acids were altered (DxxxLQY converted
to VxxxAAA; Figure 4A). Although this mutant still lo-
cated to the nucleus (see Additional file 4: Figure S1A ), in
the subcellular translocation assay, the Sox2M203–209 mu-
tant exhibited a dramatically reduced ability to change the
subcellular localization of Grg5 (Figure 5A). Moreover,
unlike WT Sox2, immune precipitation of MYC-Grg5
in COS-7 cells did not co-precipitate co-transfected
Sox2M203–209 mutant (Figure 5B). In order to determine
whether this mutation had disrupted a direct protein-
protein interaction between the Grg proteins and Sox2 an
in vitro pull down assay was used. The ability of GST-
fused Grg1 or Grg5 proteins to pull down radiolabelled
Sox2 or Sox2M203–209 was assessed. For both Grg proteins,
the Sox2M203–209 mutant resulted in a similar 4-fold
decrease in the amount of Sox2 that was co-immune
precipitated (Figure 5C). It was also noted that Grg1 was
able to pull down approximately 4-fold more Sox2 thandid Grg5 (data not shown). These data show that residues
203–209 of the Sox2 protein are necessary for a direct
interaction with both Grg1 and Grg5.
The Sox2M203–209 mutant loses repressor activity
Having established that amino acids 203–209 were required
for Grg binding, we next asked whether Sox2M203–209 was
defective in its ability to act as a gene repressor. Using the
luciferase reporter assay described above, we found that
the Sox2M203–209 mutant retained the ability to activate
both the 3xSX and the REX-regulated reporter constructs
(Figure 5D, E), indeed having a slightly stronger activator
effect on the 3xSX promoter than WT Sox2. However, the
mutant no longer significantly repressed luciferase expres-
sion of the construct driven from the GFAP promoter
even in the presence of ectopic Grg3 or Grg5 (Figure 5 F).
These results suggest that despite its inability to bind Grg
co-repressors, Sox2M203–209 retains the transcriptional ac-
tivator activity of WT Sox2, but is significantly impaired
in its ability to repress transcription from the GFAP regu-
latory sequence.
Consistent with this, when the effect of ectopic Sox2 or
the mutant Sox2 M203–209 expression on GFAP and six
genes in NSCs was assessed by qPCR, a range of levels of
Figure 3 Grgs repress Sox2 transcriptional activation activity. Co-transfected Sox2 caused an approximately 2-fold increase in luciferase
activity from the 3xSX promoter (A) or 25-fold increase from the REX promoter (B) in Cos-7 cells, but this increase was significantly inhibited when
Grg3 or Grg5 were co-transfected (A,B). (C) Co-expression of Sox2 with the GFAP-luciferase reporter construct in P19 cells caused a 2-fold
decrease in luciferase activity compared to vector alone and the presence of either Grg3 or Grg5 increased this repression (although the difference
was only significant in the presence of Grg3). (D) Cotransfected Grg3 or Grg5 caused no significant difference from controls (vector) in luciferase
activity from various promoters in P19 cells. *p = <0.05; **p = <0.01.
Figure 4 Mapping the Grg interacting region of Sox2. Schematic representation of C-terminal deletions and their effect on the ability of Sox2
to cause MYC-tagged Grg5 to translocate to the nucleus. The reduction for d1, d2, and d3 was much greater (p < 0.001) than for d4, d5 and
d6 (P = 0.01-0.05).
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Figure 5 The Sox2 M203–209 mutant does not interact with Grgs and fails to repress a reporter construct. (A) Unlike WT Sox2, the
Sox2 M203–209 mutant was unable to translocate Grg5 into the nucleus of co-transfected Cos-7 cells suggesting loss of interaction. Counting the
proportion of cells exhibiting altered distribution of MYC-Grg in cells co-expressing Sox2 revealed a highly significant reduction of about 50%
(p = 0.0002). (B) Immune precipitation of MYC-Grg5 co-transfected with WT Sox2 or with the Sox2 M203–209 mutant, showing that the mutant
failed to be co-precipitated with Grg5. (C) In an in vitro pull down assay, immunoprecipitation of GST-fused Grg1 or Grg5 reproducibly pulled-down
4–5 fold less Sox2 M203–209 than it did WT Sox2 (D) The Sox2 M203–209 mutant retained the ability to activate luciferase expression driven by the 3xSX
promoter in Cos-7 cells (the difference between this and the level induced by WT Sox2 was not statistically significant). (E) The ability of co-transfected
Sox2 M203–209 mutant to induce luciferase expression driven by the REX promoter in P19 cells was very similar to that induced by WT Sox2. (F) Unlike
WT Sox2, the Sox2 M203–209 mutant failed to repress luciferase expression driven from the GFAP promoter, and the addition of Grg3 or Grg5 had no
effect on this. *p = <0.05; **p = <0.01; ns – not significant Scale bar approximately 20 μm.
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repression by WT Sox2 and a reduced or lack of repres-
sion by the Sox2M203–209 mutant (Figure 6A).
Groucho-binding mutant of Sox2 fails to repress neural
differentiation
Overexpression of Sox2 in NSCs has been shown to inter-
fere with their ability to differentiate [18,19]. We therefore
compared the effect of overexpressing WT Sox2 to the
Sox2M203–209 mutant. Unlike control NSCs transfected
with EGFP alone, cells transfected with WT Sox2 did not
extend fine, MAP2 positive processes after 5 days in dif-
ferentiation medium, but instead, fewer cells extended
broader, shorter processes (Figure 6B,C). However, nosuch inhibition of differentiation was seen in cells trans-
fected with the Sox2M203–209 mutant.
Discussion
Sox2 is a central component of the gene regulatory net-
work that controls a range of stem cells, most notably
ESCs and NSCs. The realization that, in addition to its
role as a transcriptional activator, Sox2 might also repress
genes is relatively recent and little has been done to inves-
tigate this activity.
Here, we have shown that the number of genes re-
pressed by Sox2 in NSCs is almost identical to the number
activated and we have identified one mechanism (recruit-
ment of groucho family corepressors) by which it can
Figure 6 A Grg binding mutant of Sox2 fails to inhibit NSC differentiation. (A) Validation of the repression of NNMT, SOX8, SERPINE1, HELLS,
IGFBP2, IGFBP3 and GFAP expression using qPCR. P-values shown for 5 PCR replicates *p = <0.05; **p = <0.01. (B) Graph showing the percentage
of NSCs extending MAP2 positive processes after 5 days in differentiation medium. This was inhibited by WY Sox2 but not by the Sox2 M203–209
mutant. (C) representative examples of cells after transfection; white lines indicate length of cellular extensions. (D) Model for mechanism of Sox2
action during NSC development.
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a version of Sox2 that acts as a transcriptional activator
but now lacks that mechanism for repressor activity. This
allows us to begin to dissect the full complexity of Sox2
activity in regulating cell behaviour.
Sox2 mechanism of repression
We chose to investigate a potential interaction with Grgs
since this interaction has already been shown to mediate
repression by the HMG family protein, Tcf [14,15]. We
have shown that Sox2 does indeed, directly interact
with both full length and short forms of the Grgs.
We used a series of deletions constructs to map the puta-
tive Grg-interacting region of Sox2 to amino acids 203–209(YDVSALQY), which shows similarity to the Eh1 Grg
interacting domain, F/YxI/VxxI/L/V [20,21]. Targeted mu-
tation of this region localized the interaction to the se-
quence, DxxxLQY, which is well conserved in the SoxB1
family.
However, alternative repressor mechanism(s) may also
exist. This would provide multiple aspects to the mecha-
nisms of action of Sox2 that could therefore be inde-
pendently regulated to achieve a high level of complexity
in its biological activities. It is also possible that some of
the repressive effects of Sox2 are indirect via transcrip-
tional activation of a repressor. Our results were over a
short time scale so we do not feel that there was likely
to be sufficient time for this to occur but it remains
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tions that the repressive effects of the very similar protein,
Sox3, were mimicked by an HMG-engrailed repressor
fusion protein [22].
Relative role of transcriptional repression in Sox2 functions
Since Sox2 has traditionally been regarded as a tran-
scriptional activator, it is striking that our study revealed
that the number of genes repressed by overexpression of
Sox2 was a similar to the number of genes that were
activated. This implies that repression plays as big a
part in its biological functions as does activation.
Since the numbers of genes affected by Sox2 in our
study closely resembles the numbers of genes affected
when Sox2 was knocked down in ES cells [6,7] it seems
probable that the effects in our study represent true tar-
gets of Sox2.
It is of note that the targets of Sox2 activation are
highly enriched for regulators of Pol II transcription
whereas no such genes are repressed. This implies that a
large part of the activator function of Sox2 (approximately
25% of the genes affected by Sox2 overexpression) is to
regulate the biological activity of NSCs indirectly through
the function of downstream transcription factors, whereas
its repressor function affects the cells directly though
regulating effector genes. Since Sox2 is expressed in divid-
ing progenitor cells, the enrichment for cell cycle related
genes in those repressed by Sox2 looks at first to be coun-
terintuitive. However, this observation suggests that its
normal role may be in part to control the rate of mitosis
in those stem cells.
Previous studies have shown that the effects of SoxB1s
in inhibiting the differentiation of NSCs was mimicked
by a constitutive activator form of SoxB1 protein, while
an HMG-EnR construct caused cells to begin to differ-
entiate, suggesting that the effects of the SoxB1s were
entirely through its activity as a transcriptional activator
[18,19]. However, overexpression of the HMG-EnR con-
struct did not elicit complete differentiation as shown by
the absence of neurofilament or beta-tubulin expression
[18]. Indeed, close inspection of the published data shows
that an HMG-VP16 construct inhibits expression of early
neurogenic transcription factors, but does not appear to
completely inhibit expression of beta-tubulin.
We therefore suggest a model in which the activator
function of Sox2 promotes ‘stem cell-ness’ and so in-
hibits differentiation, but the repressor function of Sox2
is also required to inhibit differentiation, repressing
those effector genes that would be activated soon after
the cells were released from the NSC state (Figure 6C).
Consistent with this model and the published data, the
gene encoding neurofilament light chain was amongst
those genes revealed to be repressed greater than 1.5-fold
by Sox2 in our microarray analysis.Target specificity
Our observation that some genes are activated while
others are repressed in the same transfected cell popula-
tion, suggests that it is the gene target sequence that
determines whether Sox2 exerts its activator or repres-
sor activity. Activation or repression is not dictated
solely by the availability of cofactors for these functions
in a ‘cell context’ dependent manner, but is dictated by
the target gene, which presumably determines which
Sox2 cofactors are available at that regulatory region to
cause Sox2 to act as either an activator or repressor.
Conclusions
This study shows that transcriptional repression is a
major part of the mechanism by which Sox2 acts in
NSCs. In order to understand how Sox2 functions to
regulate stem cell biology, we must therefore understand
not only what is upstream and downstream of Sox2, but
also which cell type-dependent cofactors are required
for Sox2 to regulate each target and the gene sequence




The human ReNcell VM NSC line (Millipore Corp.,
Bedford, MA, U.S.A) was maintained as adherent cells
in laminin-coated flasks (Sigma Cat. No. L-2020) with
ReNcell NSC Maintenance Medium (Chemicon) sup-
plemented with 20 ng/ml growth factors (bFGF and
EGF, Invitrogen) in 50/50 mixture of Neurobasal and
DMEM F12 (Gibco) medium supplemented with Penicil-
lin/Streptomycin (Sigma), B27 and N2 (Gibco). P19CL16
mouse EC cells were maintained in Alpha Minimum
Essential Medium (GIBCO) supplemented with 10% foetal
bovine serum (FBS, Gibco) plus 0.5% Penicillin/Strepto-
mycin. COS-7 cells were maintained in Dulbecco’s Modi-
fied Eagle’s medium with 10% FBS. Differentiation of NSCs
was induced by removal of growth factors.
Immunofluorescent staining
Cells were cultured on poly-D-lysine coated coverslips,
fixed with 4% paraformaldehyde/PBS for 10 min and
permeabilised with 0.2% Triton X100/PBS for 20 min.
Blocking was carried out with 10% BSA in 0.1% Triton
X100/PBS for 30 min. Primary antibodies (MYC anti-
body (9E10), Sox2 antibody (R&D, MAB2018), MAP-2
antibody (Abcam)) and the fluorescent-conjugated sec-
ondary antibodies were incubated at room temperature
for 1 h. Staining was observed after mounting in mount-
ing medium for fluorescence with DAPI (Vector). Error
bars in Figures 1C based on counting 15 cells and 3A,
and 4A counting 100 cells.
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The human ReNcell VM NSC line (Millipore Corp.,
Bedford, MA, U.S.A) was transfected using the Mouse
NSC Nucleofector® Kit (Lonza) following the manufac-
turer’s instructions. P19CL16 mouse EC cells were trans-
fected using DharmaFECT transfection reagent (Dharmacon,
Quiagen). COS-7 cells were transfected by square pulse
electroporation; 210 volts for 50 mSec using a BTX Elec-
tro Square Porator ECM 830.
Immunoprecipitation and immunoblotting
Two days after transfection, cells were treated with the
cross-linker, 1 mM dithio-bis(succinimidyl propionat)
(DSP; Sigma) for 30 min. The cells were lysed, cleared
by centrifugation and incubated with MYC antibody-con-
jugated beads (Sigma). Eluted proteins were analysed by
SDS-PAGE and western blotting using anti-MYC and
anti-Sox2 antibodies (See supplementary material for add-
itional details).
In vitro pull down assays were performed using GST-
fusions of Grg1 and Grg5 (cloned into the pGEX4T1 vec-
tor). These proteins were induced in BL21 E.coli cells by
the addition of 0.1 mM isopropyl-D-thiogalactopyrano-
side. After 16 h growth at 18°C bacteria were harvested
and lysed. Solubility of GST-Grg proteins was increased
by an additional 1 h incubation (4°C) in lysis buffer with
1% Nonidet P-40 and 0.03% SDS. GST-fusion proteins
were subsequently incubated with S35-labelled Sox2
proteins produced in vitro using a TNT T7 kit (Promega),
with (Amersham Biosciences). GST-fusion protein were
pulled-down using Glutathione-sepharose 4B beads
(G.E Healthcare) and the presence of co-precipitated
Sox proteins assessed by exposure of a PAGE gel on a
phosphorimager.
Luciferase assay
The luciferase assay was carried out 24 h after transfection
with the dual-luciferase-reporter assay system (Promega)
following manufacturer’s instructions. Error bars represent
standard deviation based on three independent transfec-
tion experiments.
Expression profiling microarray
hNSCs were transfected with EGFP with or without
pcDNA-Sox2 or pcDNA- Sox2M203–209. After 14 h culture,
GFP-positive cells were isolated by FACS. Total RNA was
extracted using TRI reagent (Sigma) and further purified
using an RNeasy kit (QIAGEN). The RNA samples were
analysed using GeneChip® Human Genome U133 Arrays
(Affymetrix) and data were first preprocessed using the
statistical software, R with packages provide by www.
bioconductor.org. Data was preprocessed using the RMA
method [23] and filtered such that probes which gave
expression outputs below control background probes(recorded in the GeneChip) were excluded. Fold differ-
ences in expression were calculated, and annotation pack-
ages were used to assign gene information to each probe
set. The data was exported as a .txt file in order to be read
and analysed in Excel. The Excel tool PivotTable was used
to assign average expression intensity values to each gene.
Site directed mutagenesis
Point mutants were generated using the QuikChange kit
(Stratagene) according to manufacturer‘s instructions.
Quantitative RT-PCR
The extraction of total RNA from transfected hNSC using
TRI reagent (Sigma) was carried out according to the man-
ufacturer’s instructions. Total RNA samples were cleaned
up using the RNeasy Mini Kit (Qiagen). Purified total RNA
was used for the synthesis of cDNA using SuperScript III
Reverse Transcriptase (Invitrogen). The primers used in
the quantitative RT-PCR are listed below. Quantitative RT-
PCR was carried out by Rotor-Gene 6000 (Corbett/Qiagen)
with Brilliant SYBR Green QPCR Master Mix (Agilent).
The PCR programme was set at 95°C for 15 seconds, 60°C
for 20 seconds and 72°C for 20 seconds. All the quantita-
tive RT-PCR data were analysed by Rotor-Gene 6000 real-
time rotary analyzer version 1.7. The relative expression
level compared to cyclophilin B was calculated according
to Pfaffl [24]. Error bars in Figure 6A– standard deviation
based on three replicated qPCR reactions.
Details of plasmids and primers available in supple-
mentary material.
Additional files
Additional file 1: Table S1. Affymetrix expression data from GFP and
Sox2 transfected human NSCs. Data from GeneChip® Human Genome U133
Arrays. Columns G and H are anti-logged values of columns E and F allowing
un-logged ratios of expression to be clear, as shown in columns I and J.
Additional file 2: Table S2. List of GO terms of genes that increased in
expression when Sox2 was over-expressed in NSCs. N is the total number
of genes; B is the total number of genes associated with a specific GO
term; n is the flexible cutoff, i.e. the automatically determined number of
genes in the ‘target set’ (ie. affected by Sox2 overexpression) and b is the
number of genes in the ‘target set’ that are associated with a specific GO
term. Enrichment is defined as (b/n)/(B/N). FDR q-value - False Discovery
Rate analogue of the p-value.
Additional file 3: Table S3. List of GO terms of genes that decreased
in expression when Sox2 was over-expressed in NSCs. N is the total
number of genes; B is the total number of genes associated with a
specific GO term; n is the flexible cutoff, i.e. the automatically determined
number of genes in the ‘target set’ (ie. affected by Sox2 overexpression)
and b is the number of genes in the ‘target set’ that are associated with
a specific GO term. Enrichment is defined as (b/n)/(B/N). FDR q-value - False
Discovery Rate analogue of the p-value.
Additional file 4: Figure S1. Nuclear localization of various Sox2
deletion mutants (B) and the Sox2 M203–209 mutant (C) as compared to
WT Sox2 (A). Sox2 proteins were overexpressed in COS-7 cells and visualized
after 20 h using anti-sox2 antibody (green). Nuclei were counter stained
with DAPI (blue). All proteins localized exclusively to the nuclei. Scale bar
approximately 10 μm.
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CNS: Central nervous system; DAPI: 4’,6-diamidino-2-phenylindole;
EGFP: Enhanced green fluorescent protein; enR: engrailed Repressor domain;
ES cell: Embryonic stem cell; FACS: Fluorescent activated cell sorting;
GO: Gene ontology; HMG: High mobility group; iPS cell: induced Pluripotent
cell; NSC: Neural stem cell; PCR: Polymerase chain reaction; RT-PCR: Reverse
transcription PCR; VP16: Activator domain from VP16 virus; WT: Wild type.
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